Moreover, a number of preclinical and clinical studies have demonstrated that Nogo-A inhibition has a therapeutic potential for neurodegenerative conditions, such as PD [16], MS [38], spinal cord injury [39] and stroke [40]. The gene discussed is RTN4; the disease is Parkinson disease.